Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference - Cornberg, Markus; Lok, Anna Suk-Fong; Terrault, Norah A.; Zoulim, Fabien; Berg, Thomas; Brunetto, Maurizia R.; Buchholz, Stephanie; Buti, Maria; Chan, Henry L.Y.; Chang, Kyong-Mi; Dandri, Maura; Dusheiko, Geoffrey; et al. (Journal of hepatology, 2020)
Keywords: Alanine; Alanine transaminase; Alanine Transaminase - blood; Antiviral Agents - therapeutic use; Antiviral therapy; Bilirubin; Biomarkers - blood; Clinical trials; Clinical Trials, Phase III as Topic - methods; Coinfection - blood; Coinfection - drug therapy; Coinfection - virology; CpAM; Deoxyribonucleic acid; DNA; DNA, Viral - blood; Hepatitis; Hepatitis B; Hepatitis B e antigen; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; Hepatitis B virus - genetics; Hepatitis B virus - immunology; Hepatitis B, Chronic - blood; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - virology; Hepatitis D; Hepatitis D, Chronic - blood; Hepatitis D, Chronic - drug therapy; Hepatitis D, Chronic - virology; Hepatitis Delta Virus - genetics; Humans; Immunomodulatory therapy; Nucleos(t)ide analogues; Patients; Research Design; Ribonucleic acid; RNA; Sustained Virologic Response; CpAM; Antiviral therapy; Nucleos(t)ide analogues; Immunomodulatory therapy; Hepatitis B surface antigen; Hepatitis D